Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Objective: This multicenter retrospective real-world data study aimed to evaluate whether the use of a preparation containing polyphenol, vitamin D3, vitamin C, and zinc in addition to antiviral therapy was associated with symptom duration and severity, time to fever resolution, and functional recovery in children diagnosed with influenza.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

A total of 128 pediatric patients aged 4 to 10 years with a clinical and/or laboratory diagnosis of influenza were included.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Effect of Combined Polyphenol on the Disease Course in Children Diagnosed with Influenza

Study design awaiting verification · Pharmaceutics · 2026

Original publication title

Effect of Combined Polyphenol on the Disease Course in Children Diagnosed with Influenza

Eren Güzeloğlu; Vefik Arica; Belen Ateş; Taner Adigüzel; Aysun Boğa; Ali Rıza Akgün; Mehmet Tolga Köle; Ayşe Ademoğlu; Hatice Demet Kemalbay; Feyza Aydın Özgür; Hatice Yıldız Özkan; Eda Çiftçi; Hüseyin Dağ

© 2026 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Objective:

This multicenter retrospective real-world data study aimed to evaluate whether the use of a preparation containing polyphenol, vitamin D3, vitamin C, and zinc in addition to antiviral therapy was associated with symptom duration and severity, time to fever resolution, and functional recovery in children diagnosed with influenza.

Materials and Methods:

This was a five-center, multicenter, retrospective, comparative real-world data analysis. A total of 128 patients aged 4 to 10 years with a clinical diagnosis of influenza were classified into a control group receiving antiviral therapy alone (n = 64) and a combined polyphenol group receiving, in addition to antiviral therapy, a preparation containing polyphenol, vitamin D3, vitamin C, and zinc (n = 64). Clinical data were obtained from electronic patient records and parent-reported information. Symptom severity (0 to 3 ordinal score), recovery time, and functional outcomes were assessed on Days 0, 3, 5, and 7. Continuous variables were compared using the independent-samples t test, categorical variables using the chi-square or Fisher exact test, and changes over time using a repeated-measures general linear model. Statistical significance was accepted as a two-sided p value of <0.05.

Results:

In this study including 128 pediatric patients, there were no significant differences between the combined polyphenol and control groups in demographic or baseline clinical characteristics (p > 0.05). During follow-up, all symptom scores improved more rapidly and markedly in the combined polyphenol group than in the control group. By Day 3, significant differences were observed between groups in fever, cough, rhinorrhea, sore throat, fatigue, general condition, and physical activity scores (p < 0.001 for all parameters). By Day 5, almost complete resolution of symptoms (score 0) was observed in the combined polyphenol group, whereas symptoms persisted to a substantial extent in the control group (p < 0.001). The time to fever resolution was significantly shorter in the combined polyphenol group (1.84 ± 0.72 days vs. 4.5 ± 1.36 days; p < 0.001). Similarly, time to return to school (3.21 ± 0.9 days vs. 5.8 ± 1.91 days; p < 0.001) and time for parents to return to work were significantly shorter in the combined polyphenol group (p < 0.001). The need for additional healthcare visits and antipyretic use was markedly lower in the combined polyphenol group (Day 3: 20.3% vs. 53.1%; Day 5: 0% vs. 15.6%; p < 0.001 for both comparisons). Repeated-measures analyses showed a significant time-by-group interaction, indicating that the reduction in symptom scores occurred more rapidly and prominently in the combined polyphenol group (p < 0.001). Treatment was generally well tolerated in the combined polyphenol group; no serious adverse events were reported, and parent-reported tolerability was high (9.39 ± 0.7).

Conclusions:

This multicenter retrospective real-world data study suggests that the use of a preparation containing polyphenol, vitamin D3, vitamin C, and zinc in addition to antiviral therapy was associated with shorter symptom duration, lower symptom severity scores, and faster functional recovery in children diagnosed with influenza. These findings suggest that this combination may represent a promising and well-tolerated adjunctive approach in the management of pediatric influenza.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

This multicenter retrospective real-world data study aimed to evaluate whether the use of a preparation containing polyphenol, vitamin D3, vitamin C, and zinc in addition to antiviral therapy was associated with symptom duration and severity, time to fever resolution, and functional recovery in children diagnosed with influenza.

Source: Objective:

Abstract: Results

In this study including 128 pediatric patients, there were no significant differences between the combined polyphenol and control groups in demographic or baseline clinical characteristics (p > 0.05). During follow-up, all symptom scores improved more rapidly and markedly in the combined polyphenol group than in the control group. By Day 3, significant differences were observed between groups in fever, cough, rhinorrhea, sore throat, fatigue, general condition, and physical activity scores (p < 0.001 for all parameters). By Day 5, almost complete resolution of symptoms (score 0) was observed in the combined polyphenol group, whereas symptoms persisted to a substantial extent in the control group (p < 0.001). The time to fever resolution was significantly shorter in the combined polyphenol group (1.84 ± 0.72 days vs. 4.5 ± 1.36 days; p < 0.001). Similarly, time to return to school (3.21 ± 0.9 days vs. 5.8 ± 1.91 days; p < 0.001) and time for parents to return to work were significantly shorter in the combined polyphenol group (p < 0.001). The need for additional healthcare visits and antipyretic use was markedly lower in the combined polyphenol group (Day 3: 20.3% vs. 53.1%; Day 5: 0% vs. 15.6%; p < 0.001 for both comparisons). Repeated-measures analyses showed a significant time-by-group interaction, indicating that the reduction in symptom scores occurred more rapidly and prominently in the combined polyphenol group (p < 0.001). Treatment was generally well tolerated in the combined polyphenol group; no serious adverse events were reported, and parent-reported tolerability was high (9.39 ± 0.7).

Source: Results:

Abstract: Conclusions

This multicenter retrospective real-world data study suggests that the use of a preparation containing polyphenol, vitamin D3, vitamin C, and zinc in addition to antiviral therapy was associated with shorter symptom duration, lower symptom severity scores, and faster functional recovery in children diagnosed with influenza. These findings suggest that this combination may represent a promising and well-tolerated adjunctive approach in the management of pediatric influenza.

Source: Conclusions:
Authors’ abstract

Objective:

This multicenter retrospective real-world data study aimed to evaluate whether the use of a preparation containing polyphenol, vitamin D3, vitamin C, and zinc in addition to antiviral therapy was associated with symptom duration and severity, time to fever resolution, and functional recovery in children diagnosed with influenza.

Materials and Methods:

This was a five-center, multicenter, retrospective, comparative real-world data analysis. A total of 128 patients aged 4 to 10 years with a clinical diagnosis of influenza were classified into a control group receiving antiviral therapy alone (n = 64) and a combined polyphenol group receiving, in addition to antiviral therapy, a preparation containing polyphenol, vitamin D3, vitamin C, and zinc (n = 64). Clinical data were obtained from electronic patient records and parent-reported information. Symptom severity (0 to 3 ordinal score), recovery time, and functional outcomes were assessed on Days 0, 3, 5, and 7. Continuous variables were compared using the independent-samples t test, categorical variables using the chi-square or Fisher exact test, and changes over time using a repeated-measures general linear model. Statistical significance was accepted as a two-sided p value of <0.05.

Results:

In this study including 128 pediatric patients, there were no significant differences between the combined polyphenol and control groups in demographic or baseline clinical characteristics (p > 0.05). During follow-up, all symptom scores improved more rapidly and markedly in the combined polyphenol group than in the control group. By Day 3, significant differences were observed between groups in fever, cough, rhinorrhea, sore throat, fatigue, general condition, and physical activity scores (p < 0.001 for all parameters). By Day 5, almost complete resolution of symptoms (score 0) was observed in the combined polyphenol group, whereas symptoms persisted to a substantial extent in the control group (p < 0.001). The time to fever resolution was significantly shorter in the combined polyphenol group (1.84 ± 0.72 days vs. 4.5 ± 1.36 days; p < 0.001). Similarly, time to return to school (3.21 ± 0.9 days vs. 5.8 ± 1.91 days; p < 0.001) and time for parents to return to work were significantly shorter in the combined polyphenol group (p < 0.001). The need for additional healthcare visits and antipyretic use was markedly lower in the combined polyphenol group (Day 3: 20.3% vs. 53.1%; Day 5: 0% vs. 15.6%; p < 0.001 for both comparisons). Repeated-measures analyses showed a significant time-by-group interaction, indicating that the reduction in symptom scores occurred more rapidly and prominently in the combined polyphenol group (p < 0.001). Treatment was generally well tolerated in the combined polyphenol group; no serious adverse events were reported, and parent-reported tolerability was high (9.39 ± 0.7).

Conclusions:

This multicenter retrospective real-world data study suggests that the use of a preparation containing polyphenol, vitamin D3, vitamin C, and zinc in addition to antiviral therapy was associated with shorter symptom duration, lower symptom severity scores, and faster functional recovery in children diagnosed with influenza. These findings suggest that this combination may represent a promising and well-tolerated adjunctive approach in the management of pediatric influenza.

Publication and source details

Original title: Effect of Combined Polyphenol on the Disease Course in Children Diagnosed with Influenza

Eren Güzeloğlu; Vefik Arica; Belen Ateş; Taner Adigüzel; Aysun Boğa; Ali Rıza Akgün; Mehmet Tolga Köle; Ayşe Ademoğlu; Hatice Demet Kemalbay; Feyza Aydın Özgür; Hatice Yıldız Özkan; Eda Çiftçi; Hüseyin Dağ

Pharmaceutics · 2026

* Correspondence: vefikarica@hotmail.com© 2026 by the authors.2026https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.This research received no external funding.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:07:15.961228+00:00

DOI: 10.3390/pharmaceutics18070858 · PMC13415064